284 related articles for article (PubMed ID: 15345710)
1. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases.
Laederich MB; Funes-Duran M; Yen L; Ingalla E; Wu X; Carraway KL; Sweeney C
J Biol Chem; 2004 Nov; 279(45):47050-6. PubMed ID: 15345710
[TBL] [Abstract][Full Text] [Related]
2. Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).
Rafidi H; Mercado F; Astudillo M; Fry WH; Saldana M; Carraway KL; Sweeney C
J Biol Chem; 2013 Jul; 288(30):21593-605. PubMed ID: 23723069
[TBL] [Abstract][Full Text] [Related]
3. The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis.
Hoesl C; Fröhlich T; Posch C; Kneitz H; Goebeler M; Schneider MR; Dahlhoff M
Mol Oncol; 2021 Aug; 15(8):2140-2155. PubMed ID: 33786987
[TBL] [Abstract][Full Text] [Related]
4. ErbB4 expression in neural progenitor cells (ST14A) is necessary to mediate neuregulin-1beta1-induced migration.
Gambarotta G; Garzotto D; Destro E; Mautino B; Giampietro C; Cutrupi S; Dati C; Cattaneo E; Fasolo A; Perroteau I
J Biol Chem; 2004 Nov; 279(47):48808-16. PubMed ID: 15355992
[TBL] [Abstract][Full Text] [Related]
5. The single transmembrane domains of ErbB receptors self-associate in cell membranes.
Mendrola JM; Berger MB; King MC; Lemmon MA
J Biol Chem; 2002 Feb; 277(7):4704-12. PubMed ID: 11741943
[TBL] [Abstract][Full Text] [Related]
6. Negative constraints underlie the ErbB specificity of epidermal growth factor-like ligands.
van der Woning SP; van Rotterdam W; Nabuurs SB; Venselaar H; Jacobs-Oomen S; Wingens M; Vriend G; Stortelers C; van Zoelen EJ
J Biol Chem; 2006 Dec; 281(52):40033-40. PubMed ID: 17032651
[TBL] [Abstract][Full Text] [Related]
7. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy.
Shattuck DL; Miller JK; Laederich M; Funes M; Petersen H; Carraway KL; Sweeney C
Mol Cell Biol; 2007 Mar; 27(5):1934-46. PubMed ID: 17178829
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor contains both positive and negative determinants for interaction with ErbB-2/ErbB-3 heterodimers.
Stortelers C; van De Poll ML; Lenferink AE; Gadellaa MM; van Zoelen C; van Zoelen EJ
Biochemistry; 2002 Apr; 41(13):4292-301. PubMed ID: 11914075
[TBL] [Abstract][Full Text] [Related]
9. Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.
Torigoe H; Yamamoto H; Sakaguchi M; Youyi C; Namba K; Sato H; Shien K; Soh J; Suzawa K; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
Carcinogenesis; 2018 May; 39(5):719-727. PubMed ID: 29546323
[TBL] [Abstract][Full Text] [Related]
10. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation.
Gur G; Rubin C; Katz M; Amit I; Citri A; Nilsson J; Amariglio N; Henriksson R; Rechavi G; Hedman H; Wides R; Yarden Y
EMBO J; 2004 Aug; 23(16):3270-81. PubMed ID: 15282549
[TBL] [Abstract][Full Text] [Related]
11. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired.
Baulida J; Kraus MH; Alimandi M; Di Fiore PP; Carpenter G
J Biol Chem; 1996 Mar; 271(9):5251-7. PubMed ID: 8617810
[TBL] [Abstract][Full Text] [Related]
12. Vertebrate Lrig3-ErbB interactions occur in vitro but are unlikely to play a role in Lrig3-dependent inner ear morphogenesis.
Abraira VE; Satoh T; Fekete DM; Goodrich LV
PLoS One; 2010 Feb; 5(2):e8981. PubMed ID: 20126551
[TBL] [Abstract][Full Text] [Related]
13. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.
Miller JK; Shattuck DL; Ingalla EQ; Yen L; Borowsky AD; Young LJ; Cardiff RD; Carraway KL; Sweeney C
Cancer Res; 2008 Oct; 68(20):8286-94. PubMed ID: 18922900
[TBL] [Abstract][Full Text] [Related]
14. Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1.
Yi W; Holmlund C; Nilsson J; Inui S; Lei T; Itami S; Henriksson R; Hedman H
Exp Cell Res; 2011 Feb; 317(4):504-12. PubMed ID: 21087604
[TBL] [Abstract][Full Text] [Related]
15. Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis.
Stein RA; Staros JV
BMC Evol Biol; 2006 Oct; 6():79. PubMed ID: 17026767
[TBL] [Abstract][Full Text] [Related]
16. Simulation of homology models for the extracellular domains (ECD) of ErbB3, ErbB4 and the ErbB2-ErbB3 complex in their active conformations.
Franco-Gonzalez JF; Ramos J; Cruz VL; MartÃnez-Salazar J
J Mol Model; 2013 Feb; 19(2):931-41. PubMed ID: 23090500
[TBL] [Abstract][Full Text] [Related]
17. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
Feroz K; Williams E; Riese DJ
Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of inhibition of the Drosophila and mammalian EGF receptors by the transmembrane protein Kekkon 1.
Ghiglione C; Amundadottir L; Andresdottir M; Bilder D; Diamonti JA; Noselli S; Perrimon N; Carraway III KL
Development; 2003 Sep; 130(18):4483-93. PubMed ID: 12900463
[TBL] [Abstract][Full Text] [Related]
19. Ligand discrimination in signaling through an ErbB4 receptor homodimer.
Sweeney C; Lai C; Riese DJ; Diamonti AJ; Cantley LC; Carraway KL
J Biol Chem; 2000 Jun; 275(26):19803-7. PubMed ID: 10867024
[TBL] [Abstract][Full Text] [Related]
20. Ligand-induced, p38-dependent apoptosis in cells expressing high levels of epidermal growth factor receptor and ErbB-2.
Tikhomirov O; Carpenter G
J Biol Chem; 2004 Mar; 279(13):12988-96. PubMed ID: 14711810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
